## LARisk: An R package for lifetime attributable risk from radiation exposure

Juhee Lee<sup>1</sup>, Young Min Kim<sup>1\*</sup>, Yeongwoo Park<sup>1</sup>, Eunjin Jang<sup>1</sup>, Jinkyung Yoo<sup>1</sup>, Songwon Seo<sup>2</sup>, Eun Shil Cha<sup>3</sup>, Won Jin Lee<sup>3</sup>

 Department of Statistics, Kyungpook National University, Daegu, Republic of Korea
 Laboratory of Low Dose Risk Assessment, National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
 Department of Preventive Medicine, College of Medicine, Korea University, Seoul, Republic of Korea

\* Corresponding author Email: kymmyself@knu.ac.kr

## Abstract

The lifetime radiation associated risk of cancer incidence has been of interest at least seventy years after atomic bombings of Hiroshima and Nagasaki in 1945. Since most of radiation epidemiological studies are retrospective, it is important to assess the potential magnitude of radiation-related cancer risk. The R-package so-call **LARisk** implements to easily calculate lifetime attributable risks (LAR) of radiation associated cancer incidence presenting bootstrap-based confidence intervals of the estimated risks. The main characteristics of the **LARisk** package are to flexibly compute the LAR-associated risks, effectively summarize large data, and promptly update domain-knowledge such as new regression coefficients for excess relative risk or excess absolute risk models, population information, etc. The manuscript provides a complete guide for usage of the **LARisk** package, which will enable to contribute the prospective studies in radiation epidemiology.

**Keywords:** Lifetime attributable risk, Prospective study, Radiation epidemiology, Radiation-associated cancer

### Introduction

The lifetime radiation related risk of cancer incidence remains elevated for at least seventy years after atomic bombings of Hiroshima and Nagasaki, Japan in 1945 [1]. Estimating radiation related cancer risk has made steady progress [1,2], but most studies have been retrospective. Forward projection of radiation related cancer risk is essential to allow predictive studies of irradiated groups to ultimately control excess radiation exposure occurring, e.g. from medical radiography (computed tomography, CT) scans [3,4].

There are several reports to discuss lifetime radiation related cancer risk projection models. The U.S. Nuclear Regulatory Commission developed the NUREG model to predict health effects from radiation exposure at nuclear power plants, considering the dose and dose-rate effectiveness factor (DDREF) and age-specific risk coefficients [5]. The U.S. National Research Council proposed the BEIR VII model [6] for radiation exposed groups, focusing on cancer risk projection from low linear energy transfer

> (LET) radiation exposure with weighted average estimates from excess relative risk (ERR) and excess absolute risk (EAR) models [6]. The BEIR VII risk models were based primarily on the Life Span Study (LSS) study from the Radiation Effects Research Foundation (RERF), which has advantages of its large population, including of both sexes and all ages, long follow-up, and high-quality mortality and cancer incidence data [6]. However, LSS is based on single acute exposure and still limited in its ability to precisely estimate site-specific cancer risks. Therefore, we acknowledge that the BEIR VII models need to be updated with other studies of chronic low-level radiation exposure with the longer duration follow-up.

> The lifetime attributable risk (LAR) means the number of excess event incidences for an irradiated group compared with a non-radiation exposed group. The LAR risk projection model is defined as

$$\int_{a_1+L}^{a_{\max}} M(D,e,a,s) \frac{S(a,s)}{S(e,s)} da,$$
(1)

where L is the latency period for each cancer, M(D, e, a, s) is a risk model, and the ratio S(a, s)/S(e, s) is the conditional probability of a person alive and cancer-free at age-at exposure (e) to approach an attained age (t). We used cancer-free survival function after removing cancer incidence in the risk projection models [7]. In radiation epidemiology, LAR is the probability of premature cancer incidence attributable to radiation exposure in a representative member of the population [8–10] over their lifetime. World Health Organization (WHO) used LAR for Fukushima health risk assessment [11], and many other studies also have forecast radiation related cancer risk using LAR [3, 12–22].

The US National Cancer Institute 'RadRAT' program estimates lifetime risk of cancers induced by radiation exposure [23] based on BEIR VII [6], which estimated radiation related cancer risk transferred from Japanese (atomic bomb survivors) to US populations, and considered uncertainties related to risk model regression coefficients, e.g. ERR and EAR models (see [23] and [6] for more details), minimum latency, DDREF and radiation dose exposure distributions and population transfer weights. The 'RadRAT' program can be accessed for free at https://radiationcalculators.cancer.gov/radrat/ and is widely used to assess lifetime cancer risks attributable to radiation [20, 24, 25]. Although 'RadRAT' was designed to be easy and simple to use, it is difficult to flexibly use batch files for large data analyses or multiple cases, or ensure timely knowledge updates, e.g. baseline incidence rate in a specific population, life tables, etc. Thus, we developed an **LARisk** R package to calculate lifetime attributable risk for radiation related cancer built over the online RadRAT program. LARisk provides significantly enhanced flexibility by incorporating functions to project LAR for the batch file considering modified baseline incidence rate and/or population transfer weights, and DDREF application and a summary function based on average LAR for each case. In addition, LARisk uses the parametric bootstrap method to compute risk estimates and confidence intervals because the population distributions for uncertainties are known. The parametric bootstrap method is more powerful and provides small variances compared with the nonparametric bootstrap if the distribution assumption is known and the sample sizes are relatively small.

The remainder of this paper is organized as follows. Section LAR models describes the LAR risk models in detail, including the underlying ERR and EAR functions and discusses statistical uncertainties. Section Illustration of LARisk package discusses input information, output values, arguments, and result interpretation in the LARisk package; briefly describes LARisk options; Section An example with chronic exposure rate uses data examples to describe how to use LARisk. Finally, Section Concluding remarks summarizes the paper.

15

16

17

18

19

20

21

22

23

24

25

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

## LAR models

#### **Risk model**

Risk models for the **LARisk** package were based on those developed for the RadRAT program to estimate lifetime risk following low-dose radiation exposure. ERR (Excess Relative Risk) and EAR (Excess Absolute Risk) models were used for exposed individuals compared with unexposed individuals, based on a dose response function,  $\rho(D)$  with radiation dose D in Gray (Gy), and effect modification,  $\varepsilon(\mathbf{X}) = \exp(\alpha^T \mathbf{X})$ where **X** is a vector of several covariates including age at exposure, attained age, sex, etc. and  $\alpha$  is a vector of regression coefficients.  $\rho(D)$  can be linear, linear-quadratic, quadratic, linear-threshold, nonparametric, etc. For example,

 $\rho(D) = \begin{cases} \beta_1 D & \text{Linear} \\ \beta_1 D + \beta_2 D^2 & \text{Linear-Quadratic} \\ \beta_2 D^2 & \text{Quadratic.} \end{cases}$ 

See [6], [1], [26], [27] and [28] for more details.

**LARisk** incorporates both ERR and EAR for a risk model (1) to compute LAR estimates of solid cancer and leukemia. The standard form of ERR or EAR models for solid cancer, except thyroid and breast, is defined as

$$\beta_s D \exp\left[\alpha_1 e^* + \alpha_2 \log\left(\frac{a}{60}\right)\right],\tag{2}$$

where the risk is assumed to be linearly related to the radiation dose, a is attained age, and e is age at exposure, which are considered to be effect modifications where

$$e^* = \begin{cases} (e-30)/10 & \text{for} \quad e < 30\\ 0 & \text{for} \quad e \ge 30. \end{cases}$$

The form for thyroid and breast cancer is slightly different from the standard model. Thyroid only depends on age at exposure effect modification. The breast cancer model is defined as  $\begin{bmatrix} a & b \\ a & b \end{bmatrix}$ 

$$\beta_s D \times \exp\left[\alpha_1 e^{**} + \alpha_2 \log\left(\frac{a}{50}\right)\right],$$
(3)

where  $e^{**} = (e - 25)/10$ ,  $\alpha_2$  is equal to 3.5 for  $a \leq 50$  and 1.0 elsewhere. Gallbladder, brain/CNS, and thyroid cancers only consider a risk model based on ERR to calculate LAR, and breast cancer utilizes a risk model based on only EAR. A standard form of a risk model for leukemia takes the model as

$$\beta_s D(1+\theta D) \exp\left[\alpha_1 e^* + \alpha_2 \log\left(\frac{t}{25}\right) + \alpha_2 e^* \log\left(\frac{t}{25}\right)\right],\tag{4}$$

which is linear-quadratic in dose and age at exposure, and time since exposure (t) is considered as the effect modification. For chronic exposure, the risk model is linear with dose, i.e.,  $\theta = 0$ . A generalized nonlinear model, in particular a Poisson nonlinear model, is required to directly estimate the parameters [6, 26, 28, 29].

It is possible that LAR can be obtained from the multiplicative or additive model controlling weights. The multiplicative model assumes that radiation induced excess cancer risk proportionally increases with baseline risk as

$$\begin{split} \text{Multiplicative model} &: M(D, e, a, s) &= & \text{ERR}(D, e, a, s) \times \lambda_0(a, s) \\ &= & \text{ERR}(D, e, a, s) \times m(a) \times \frac{S(a, s)}{S(e, s)}, \end{split}$$

64

65

66

67

68

69

70

71

72

73

74

75

76

77

80

81

82

87

88

89

90

91

92

where  $\lambda_0(a, s)$  is the excess risk for non-exposed group. On the other hand, the additive model assumes that radiation induced excess cancer risk increases independently of baseline risk as

Additive model : 
$$M(D, e, a, s) = \text{EAR}(D, e, a, s) \times \frac{S(a, s)}{S(e, s)}$$
.

Both LAR<sub>ERR</sub> and LAR<sub>EAR</sub>, are LAR components based on ERR and EAR models, respectively, defined as

$$LAR_{ERR} = \int_{a_1+L}^{a_{max}} ERR(D, e, a, s) \times m(a) \times \frac{S(a, s)}{S(e, s)} da$$
$$LAR_{EAR} = \int_{a_1+L}^{a_{max}} EAR(D, e, a, s) \times \frac{S(a, s)}{S(e, s)} da,$$
(5)

where m(a) is population cancer incidence rate, and S(a, s)/S(e, s) is the probability of surviving to age a, conditional on survival to age e, given sex s. Thus, the LAR model in the **LARisk** package is computed as

$$LAR = \frac{w \times LAR_{ERR} + (1 - w) \times LAR_{EAR}}{DDREF}$$
 for all solid cancer,

and

$$LAR = (LAR_{ERR})^w \times (LAR_{EAR})^{1-w}$$
 for leukemia,

where w is a population transfer weight.

#### Uncertainty assessment

Uncertainties including statistical uncertainties must be considered when calculating LAR, since we use probability distribution functions based on radiation epidemiology and Monte Carlo (MC) simulation. The uncertainties are as follows.

1.	risk model coefficients,	108
2.	dose and dose-rate effectiveness factor,	109
3.	minimum latency,	110
4.	risk population transfer between populations (e.g. Japan to US),	111
5.	radiation doses, and	112

6. baseline incidence rate.

Uncertainties 1–4 including statistical uncertainties have the most critical impact to assess lifetime cancer risk attributable to radiation, whereas uncertainties 5 and 6 cause LAR variability regardless of the model. The baseline incidence rate in particular (uncertainty 6) differs with population and year, generating different incidence rate distributions by age.

To calculate radiation induced future cancer risk, we substitute the formula (2) into (5) for solid cancer as

$$\text{LAR}_{\text{ERR}} = \int_{e+L}^{a_{max}} \beta_{\text{ERR},s} \times D \times \exp\left\{\alpha_{\text{ERR},1}e^* + \alpha_{\text{ERR},2}\log\left(\frac{a}{60}\right)\right\} \times m(a) \times \frac{S(a,s)}{S(e,s)} \, \mathrm{d}a$$

$$LAR_{EAR} = \int_{e+L}^{a_{max}} \beta_{EAR,s} \times D \times \exp\left\{\alpha_{EAR,1}e^* + \alpha_{EAR,2}\log\left(\frac{a}{60}\right)\right\} \times \frac{S(a,s)}{S(e,s)} da.$$
(6)

The regression coefficients,  $\beta_{\text{ERR},s}$ ,  $\beta_{\text{EAR},s}$ ,  $\alpha_{\text{ERR},1}$ ,  $\alpha_{\text{EAR},1}$ ,  $\alpha_{\text{ERR},2}$ , and  $\alpha_{\text{EAR},1}$ , were determined from radiation epidemiologic research with atomic bomb (A-bomb) survivors

94

95

96

97

98

102

103

104

113

119

	ERR regressi	ion coefficients for	solid ca	ncers
Cancer site	$\beta_{Male}$	$\beta_{Female}$	$\alpha_1$	$\alpha_2$
Oral	0.23 (< 0.0 - 0.66)	0.53 (0.13 - 1.24)	-0.30	-1.40
Esophagus	0.51 (< 0.0 - 1.13)	$0.82 \ (<0.0-3.10)$	-0.30	-1.40
Stomach	$0.21 \ (0.11 - 0.40)$	$0.48~(0.31{-}0.73)$	-0.30	-1.40
Colon	$0.63\ (0.37{-}1.10)$	0.43~(0.19 - 0.96)	-0.30	-1.40
Rectum	0.12 (< 0.0 - 0.38)	0.12 (< 0.0 - 0.38)	-0.30	-1.40
Gallbladder	-0.018 (<0.0-0.29)	-0.018 (<0.0-0.29)	-0.30	-1.40
Pancreas	0.36 (< 0.0 - 0.88)	0.36 (< 0.0 - 0.88)	-0.30	-1.40
Liver	$0.32 \ (0.16-0.64)$	0.32 (0.10 - 1.00)	-0.30	-1.40
Lung	$0.32 \ (0.15 - 0.70)$	$1.4 \ (0.94 - 2.10)$	-0.30	-1.40
Breast	-	-	-	-
Ovary	-	0.38(0.10 - 1.40)	-0.30	-1.40
Uterus	-	0.05 (< 0.0 - 0.22)	-0.30	-1.40
Prostate	0.12 (< 0.0 - 0.69)	-	-0.30	-1.40
Bladder	0.50(0.18 - 1.40)	1.65 (0.69 - 4.00)	-0.30	-1.40
Kidney	0.34 (< 0.0 - 1.00)	0.34 (< 0.0 - 1.00)	-0.30	-1.40
Brain/CNS	0.71(0.26-1.34)	0.24(0.09-0.47)	-0.30	-1.40
Thyroid	$0.53 \ (0.14 - 2.00)$	$1.05\ (0.28-3.90)$	-0.83	0.00
Remainder	0.84~(0.451.69)	0.80~(0.331.93)	-0.30	-1.40
	EAR regressi	ion coefficients for	solid ca	ncers
Cancer site	${f EAR}\ {f regression}\ {f eta}_{Male}$	ion coefficients for $\beta_{Female}$	solid ca $\alpha_1$	$\alpha_2$
Cancer site Oral	EAR regression $\beta_{Male}$ 0.44 (0.08–1.10)	ion coefficients for $\beta_{Female}$ 0.29 (0.06–0.66)	solid ca $\alpha_1$ -0.41	$\frac{\alpha_2}{0.50}$
Cancer site Oral Oesophagus	$\begin{array}{c} {\color{red} {\bf EAR \ regress}}\\ {\color{red} \beta_{Male}}\\ \hline 0.44 \ (0.08{-}1.10)\\ 0.88 \ (0.11{-}2.10) \end{array}$		solid ca $\alpha_1$ -0.41 -0.41	$\frac{\alpha_2}{0.50}$ 2.80
Cancer site Oral Oesophagus Stomach	$\begin{array}{c} \textbf{EAR regress}\\ \hline \beta_{Male} \\ \hline 0.44 \; (0.081.10) \\ 0.88 \; (0.112.10) \\ 4.90 \; (2.708.90) \end{array}$		solid ca $\alpha_1$ -0.41 -0.41 -0.41	$     \frac{\alpha_2}{0.50} \\     2.80 \\     2.80    $
Cancer site Oral Oesophagus Stomach Colon	$\begin{array}{c} \textbf{EAR regress}\\ \hline \beta_{Male} \\ \hline 0.44 \; (0.08 {-} 1.10) \\ 0.88 \; (0.11 {-} 2.10) \\ 4.90 \; (2.70 {-} 8.90) \\ 3.20 \; (1.80 {-} 5.60) \end{array}$		$\begin{array}{c} \text{solid ca} \\ \hline \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$     \frac{\alpha_2}{0.50} \\     2.80 \\     2.80 \\     2.80     2.80     $
Cancer site Oral Oesophagus Stomach Colon Rectum	$\begin{array}{c} \textbf{EAR regress}\\ \hline \beta_{Male} \\ \hline 0.44 \; (0.08{-}1.10) \\ 0.88 \; (0.11{-}2.10) \\ 4.90 \; (2.70{-}8.90) \\ 3.20 \; (1.80{-}5.60) \\ 0.34 \; (0.09{-}1.10) \end{array}$		solid ca $\alpha_1$ -0.41 -0.41 -0.41 -0.41 -0.41	$     \frac{\alpha_2}{0.50} \\     2.80 \\     2.80 \\     2.80 \\     2.80 \\     2.80 \\     2.80 $
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder	$\begin{array}{c} \textbf{EAR regress}\\ \hline \beta_{Male}\\ \hline 0.44 \; (0.08{-}1.10)\\ 0.88 \; (0.11{-}2.10)\\ 4.90 \; (2.70{-}8.90)\\ 3.20 \; (1.80{-}5.60)\\ 0.34 \; (0.09{-}1.10)\\ \hline \end{array}$		solid ca $\alpha_1$ -0.41 -0.41 -0.41 -0.41 -0.41 -0.41	$ \frac{\alpha_2}{0.50} \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ -  $
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas	$\begin{array}{c} \textbf{EAR regressing}\\ \beta_{Male}\\ \hline 0.44 \; (0.08{-}1.10)\\ 0.88 \; (0.11{-}2.10)\\ 4.90 \; (2.70{-}8.90)\\ 3.20 \; (1.80{-}5.60)\\ 0.34 \; (0.09{-}1.10)\\ \hline 0.49 \; (0.09{-}1.10)\\ \end{array}$	$ \begin{array}{c} \hline \beta_{Female} \\ \hline 0.29 \ (0.06-0.66) \\ 0.14 \ (<0.0-0.63) \\ 4.90 \ (3.20-7.30) \\ 1.60 \ (0.80-3.20) \\ 0.34 \ (0.09-1.10) \\ \hline 0.49 \ (0.09-1.10) \end{array} $	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{c} \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ - \\ 2.80 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver	$\begin{array}{c} \textbf{EAR regress}\\ \hline \beta_{Male} \\ \hline 0.44 \; (0.08 - 1.10) \\ 0.88 \; (0.11 - 2.10) \\ 4.90 \; (2.70 - 8.90) \\ 3.20 \; (1.80 - 5.60) \\ 0.34 \; (0.09 - 1.10) \\ \hline 0.49 \; (0.09 - 1.10) \\ 2.20 \; (0.90 - 5.30) \end{array}$		$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ - \\ 2.80 \\ 4.10 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\\hline\\ 0.44 \; (0.08-1.10)\\ 0.88 \; (0.11-2.10)\\ 4.90 \; (2.70-8.90)\\ 3.20 \; (1.80-5.60)\\ 0.34 \; (0.09-1.10)\\ 0.49 \; (0.09-1.10)\\ 2.20 \; (0.90-5.30)\\ 2.30 \; (1.10-5.00)\\ \end{array}$		$\begin{array}{c} \text{solid ca} \\ \hline \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \end{array}$		$\begin{array}{c} \text{solid ca} \\ \hline \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.50 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \end{array}$	$\begin{array}{c} & \beta_{Female} \\ \hline 0.29 & (0.06-0.66) \\ 0.14 & (<0.0-0.63) \\ 4.90 & (3.20-7.30) \\ 1.60 & (0.80-3.20) \\ 0.34 & (0.09-1.10) \\ \hline 0.49 & (0.09-1.10) \\ 1.00 & (0.40-2.50) \\ 3.40 & (2.30-4.90) \\ 10.00 & (7.00-14.20) \\ 0.70 & (0.20-2.10) \end{array}$	$\begin{array}{c} \text{solid ca} \\ \hline \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.50 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ \hline 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus	$\begin{array}{c} \textbf{EAR regressing}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline - \\ - \\$	$\begin{array}{c} \hline & \beta_{Female} \\ \hline 0.29 & (0.06-0.66) \\ 0.14 & (<0.0-0.63) \\ 4.90 & (3.20-7.30) \\ 1.60 & (0.80-3.20) \\ 0.34 & (0.09-1.10) \\ \hline & - \\ 0.49 & (0.09-1.10) \\ 1.00 & (0.40-2.50) \\ 3.40 & (2.30-4.90) \\ 10.00 & (7.00-14.20) \\ 0.70 & (0.20-2.10) \\ 1.20 & (<0.0-2.60) \\ \end{array}$	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.50 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \\ 2.80 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus Prostate	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \\ \hline \\ 0.11 & (<0.0-1.0)\\ \end{array}$	ion coefficients for $\beta_{Female}$ 0.29 (0.06–0.66) 0.14 (<0.0–0.63) 4.90 (3.20–7.30) 1.60 (0.80–3.20) 0.34 (0.09–1.10) - 0.49 (0.09–1.10) 1.00 (0.40–2.50) 3.40 (2.30–4.90) 10.00 (7.00–14.20) 0.70 (0.20–2.10) 1.20 (<0.0–2.60)	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.50 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ \hline 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus Prostate Bladder	$\begin{array}{c} \textbf{EAR regressing}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \\ \hline \\ 0.11 & (<0.0-1.0)\\ 1.20 & (0.40-3.70)\\ \end{array}$	$\begin{array}{c} & \beta_{Female} \\ \hline 0.29 & (0.06-0.66) \\ 0.14 & (<0.0-0.63) \\ 4.90 & (3.20-7.30) \\ 1.60 & (0.80-3.20) \\ 0.34 & (0.09-1.10) \\ \hline 0.49 & (0.09-1.10) \\ 1.00 & (0.40-2.50) \\ 3.40 & (2.30-4.90) \\ 10.00 & (7.00-14.20) \\ 0.70 & (0.20-2.10) \\ 1.20 & (<0.0-2.60) \\ \hline 0.75 & (0.30-1.70) \end{array}$	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ \hline 2.80 \\ \hline 2.80 \\ \hline 3.50 \\ 1.00 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 6.00 \\ \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus Prostate Bladder Kidney	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \\ \hline \\ \hline \\ 0.11 & (<0.0-1.0)\\ 1.20 & (0.40-3.70)\\ 0.31 & (0.08-0.68)\\ \end{array}$	$\begin{array}{c} \hline & \beta_{Female} \\ \hline 0.29 & (0.06-0.66) \\ 0.14 & (<0.0-0.63) \\ 4.90 & (3.20-7.30) \\ 1.60 & (0.80-3.20) \\ 0.34 & (0.09-1.10) \\ \hline 0.49 & (0.09-1.10) \\ 1.00 & (0.40-2.50) \\ 3.40 & (2.30-4.90) \\ 10.00 & (7.00-14.20) \\ 0.70 & (0.20-2.10) \\ 1.20 & (<0.0-2.60) \\ \hline \\ \hline \\ 0.75 & (0.30-1.70) \\ 0.31 & (0.08-0.68) \end{array}$	$\begin{array}{c} \text{solid ca} \\ \hline \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \end{array}$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 6.00 \\ 2.80 \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus Prostate Bladder Kidney Brain/CNS	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \\ \hline \\ \hline \\ 0.11 & (<0.0-1.0)\\ 1.20 & (0.40-3.70)\\ 0.31 & (0.08-0.68)\\ \hline \\ \hline \\ \end{array}$	ion coefficients for $\beta_{Female}$ 0.29 (0.06–0.66) 0.14 (<0.0–0.63) 4.90 (3.20–7.30) 1.60 (0.80–3.20) 0.34 (0.09–1.10) - 0.49 (0.09–1.10) 1.00 (0.40–2.50) 3.40 (2.30–4.90) 10.00 (7.00–14.20) 0.70 (0.20–2.10) 1.20 (<0.0–2.60) - 0.75 (0.30–1.70) 0.31 (0.08–0.68) -	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ \hline 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 6.00 \\ 2.80 \\ \hline - \end{array}$
Cancer site Oral Oesophagus Stomach Colon Rectum Gallbladder Pancreas Liver Lung Breast Ovary Uterus Prostate Bladder Kidney Brain/CNS Thyroid	$\begin{array}{c} \textbf{EAR regression}\\ \beta_{Male}\\ \hline 0.44 & (0.08-1.10)\\ 0.88 & (0.11-2.10)\\ 4.90 & (2.70-8.90)\\ 3.20 & (1.80-5.60)\\ 0.34 & (0.09-1.10)\\ \hline 0.49 & (0.09-1.10)\\ 2.20 & (0.90-5.30)\\ 2.30 & (1.10-5.00)\\ \hline \\ \hline \\ \hline \\ 0.11 & (<\!0.0\!-\!1.0)\\ 1.20 & (0.40\!-\!3.70)\\ 0.31 & (0.08\!-\!0.68)\\ \hline \\ \hline$	ion coefficients for $\beta_{Female}$ 0.29 (0.06–0.66) 0.14 (<0.0–0.63) 4.90 (3.20–7.30) 1.60 (0.80–3.20) 0.34 (0.09–1.10) - 0.49 (0.09–1.10) 1.00 (0.40–2.50) 3.40 (2.30–4.90) 10.00 (7.00–14.20) 0.70 (0.20–2.10) 1.20 (<0.0–2.60) - 0.75 (0.30–1.70) 0.31 (0.08–0.68) -	$\begin{array}{c} \text{solid ca} \\ \alpha_1 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.41 \\ -0.50 \\ -0.41 \\ -0.$	$\begin{array}{r} \alpha_2 \\ \hline \alpha_2 \\ \hline 0.50 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ - \\ 2.80 \\ 4.10 \\ 5.20 \\ 3.50, 1.00 \\ 2.80 \\ 2.80 \\ 2.80 \\ 2.80 \\ 6.00 \\ 2.80 \\ - \\ - \\ - \\ - \\ - \end{array}$

Table 1. The regression coefficients of all radiation related solid cancer risk models [6,23]

Note that the values in the parentheses represent 95% confidence intervals for each regression coefficient.

at RERF, which has conducted health related research among A-bomb survivors in Hiroshima and Nagasaki, Japan, for more than 70 years. Tables 1 and 2 show the regression coefficients for solid cancers and leukemia, respectively. For leukemia, we replace the formula (2) by (4) to derive a similar expression to the formula (6).

The uncertainties of risk model coefficients for solid cancers focus on sex-specific main effect parameters, whereas other parameters are specific constants derived from

128

	ERR and EA	R models for lea	ıkemia
	$\beta_{Male}$	$\beta_{Female}$	$\alpha_1$
ERR	$1.10\ (0.10 - 2.60)$	1.20(0.10-2.90)	$-0.40 \ (-0.78 \ \text{to} \ 0.00)$
EAR	$1.62 \ (0.10 - 3.60)$	$0.93 \ (0.10 - 2.00)$	$0.29 \ (0.00 - 0.62)$
			0
	$lpha_2$	$lpha_3$	$\theta$
ERR	-0.48 (-1.10  to  0.20)	$0.42 \ (0.00-0.96)$	$0.87 \ (0.16 - 15.00)$
EAR	0.00	0.56~(0.310.85)	$0.88 \ (0.16 - 15.00)$

 Table 2. Regression coefficients for radiation related leukemia risk models [6,23]

Note that the values in the parentheses represent 95% confidence intervals for each regression coefficient.

A-bomb survivor epidemiology studies. Table 1 shows uncertainties for ERR and EAR 129 model parameters. Dose coefficient,  $\beta$ , for stomach, colon, liver, lung, breast, ovary, 130 bladder, and thyroid cancer is assumed to follow log-normal distribution, hence 131 regression coefficient distributions in LAR models for prostate and uterus cancer are 132 also considered to be normally distributed. Uncertainty in  $\beta$  is described by cumulative 133 distribution functions (CDFs) for oral, oesophagus, gallbladder, pancreas, rectum, 134 kidney, and brain/CNS cancers.  $\alpha_2$  of breast cancer has two values. See the formula 3. 135 In contrast to solid cancer, uncertainty for leukemia is associated with five parameters. 136 Since the covariance matrix for regression coefficients in the leukemia LAR model 137 should be considered, we calculate an approximate estimator for lifetime risk variance 138 using the delta method following the BEIR VII committee [6]. 139

The dose and dose-rate effectiveness factor (DDREF) combines two concepts of a low-dose effectiveness (LDEF) and a dose-rate effectiveness factor (DREF) [6,30,31]. LDEF means a ratio of the slope of a linear-quadratic dose-response function for acute exposure and the slope of the linear term of the same model, whereas DREF is computed when an acute exposure is divided and the number of fractions is large enough. ICRP suggested to utilize a DDREF of 2 to reduce solid cancer rates obtained from moderate-to-high acute dose studies for low-dose or low-dose rate exposures [31,32]. The DDREF distribution is considered as a lognormal with geometric mean= 1.5 and standard deviation= 1.35 [23]. DDREF is always applied for chronic exposure without dose-dependence. In acute exposures, DDREF is applied by comparing dose limit,  $D_L$ , and exposure dose. If dose  $< D_L$  (generated 30 – 200 mGy using log-uniform distribution), DDREF is considered as used. DDREF is not applied for leukemia, because the uncertainty associated with low-dose risks is modeled using a linear term.

Latency uncertainty for radiation-induced cancers should be considered, because each person has cancer different development time after radiation exposure. Latency distribution is commonly represented by an S-shaped curve with the parameter in the center of the S-shaped function generated from the triangular distribution for solid cancer, thyroid and leukemia as T(5, 7.5, 10), T(3, 5, 7) and T(2, 2.25, 2.5), respectively. An uncertain latency adjustment is between 4 and 11 years after radiation exposure for solid cancer, 2.5 and 7.6 years for thyroid cancer, and 0.4 and 4.1 years for leukemia [33].

We must also consider effect of transferring the risk from Japanese population to 160 population of interest. Because parameters of risk model coefficients are commonly 161 obtained using the Japanese A-bomb survivors cohort, the effect is explained by the 162 weighted mean of LAR values based on ERR and EAR model estimates. Initially we use 163 the RadRAT weight to transfer the risk from Japanese to US populations. Thus, the 164 weight w = 0.7 is assigned to the ERR model and the remaining (1 - w = 0.3) weight to 165 the EAR model for most cancers. Lung cancer weight is reversed, and only the EAR 166 model for breast is used. For thyroid, gallbladder, and brain/CNS, only ERR is used for 167 calculation of LAR. 168

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

> Radiation dose uncertainty can be applied to a fixed value or various probability distributions, including lognormal, normal, triangular, log-triangular, uniform, and log-uniform.

The baseline incidence rate depends on population information.

#### Parametric bootstrap

**Algorithm 1:** Computation of parametric bootstrap confidence intervals for risk estimates

**Result:** a bootstrap  $(1 - \alpha) \times 100\%$  confidence interval for LAR Compute the LAR estimates such as LAR; for *Generate bootstrap samples from distributions of uncertainties*  $b = 1, \dots, B$ do | Calculate the LAR estimates; end  $100(\alpha/2)\%$  and  $100(1 - \alpha/2)\%$  percentiles of LAR are the  $(1 - \alpha) \times 100$ bootstrap confidence interval for the LAR;

Since uncertainties' distributions for estimation of LAR are already known, we apply 175 the parametric bootstrap to compute the confidence intervals for all risk estimates. The 176 parametric bootstrap needs distribution assumption for generation and the other 177 procedure is identical to the general nonparametric bootstrap. The parametric 178 bootstrap is more powerful, in that the method provides small variances compared with 179 the nonparametric bootstrap if the distribution is assumed to be right and the sample 180 sizes are relatively small. The parametric bootstrap algorithm is provided in Algorithm 181 1. 182

## Illustration of LARisk package

#### Main arguments

The **LARisk** package has 3 main functions for estimating lifetime attributable risks such as **LAR**, **LAR\_batch** and **LAR\_group**. The primary argument for the **LAR** function is as follows.

LAR(data, basedata, sim=300, seed=99, current=as.numeric(substr (Sys.Date(),1,4)), ci=0.9, weight=NULL, DDREF=TRUE, basepy =1e+05)

The argument 'data' should include some prerequisite information such as sex, and birth year(s), exposure year, distributions of exposure dose, radiation dose, cancer sites, and exposure rate, shown as follows.

```
> data=data.frame(sex = 'male', birth = 1900, exposure = 1980,
    site = 'stomach', exposure_rate = 'chronic', dosedist = '
    fixedvalue', dose1 = 10, dose2=NA, dose3=NA)
```

For 'site', we provide the irradiated organ or cancer site. In 'dosedist', 'dose1', 'dose2', 203 and 'dose3' arguments, we insert the distribution of the exposure dose such as 204 'fixedvalue', 'lognormal', 'normal', 'triangular', 'logtriangular', 'uniform' or 'loguniform' 205 with appropriate parameters for each distribution. For instance, if the exposure dose 206 has a normal distribution with mean of 2.3 and standard deviation of 0.8, we set 207 'dose1=2.3', 'dose2=0.8', and 'dose3=NA'. If the dose has fixed value of 3.2, 'dose1=3.2', 208 'dose2=NA' and 'dose3=NA' should be employed. If new population information should 209 be considered, lifetime and cancer incidence rate tables are employed in a 'basedata' 210 argument as follows. 211

183

184

172

173

174

193

194

195

196 188

199

200

LAR(data, basedata	= list(lifeTable, incidenceTable))
# lifeTable :	lifetime table
<pre># incidenceTable:</pre>	cancer incidence rate table

LARisk has default for these tables, which were made in 2010 and 2018, South Korea such as 'life2010', 'incid2010', 'life2018' and 'incid2018'. Lifetime and cancer incidence rate tables should also have the specified format as follows.

> head(in in 2	cid2010) 010.	## cancer	incidence	rate	table	of	$\mathrm{the}$	Korean
Site Age 1 oral 2 oral	Rate_m Ra 0 0.2 1 0.2	te_f 0.1 0.1						

Also, the cancer incidence rate table consists of 'Site', 'Age', 'Rate\_m', and 'Rate\_f' where 'Rate\_m' and 'Rate\_f' are incidence rates of each cancer site according to male and female, respectively.

The argument 'weight' is employed to compute LAR values through the weighted average of LAR values based on ERR and EAR models. For example, if the 'weight' for LAR based on between EAR and ERR models for stomach cancer is set to 0.5, run the below code.

LAR(data,	basedata ,	weight=list	(stomach = 0	(.5))
-----------	------------	-------------	--------------	-------

**LARisk** sets the default weights to 0.7 for most cancers, 0.3 for lung cancer, 0.0 for breast and 1.0 for thyroid for LAR based on EER (see Table 3).

#### Table 3. Weights for each cancer site

Cancer site	ERR	EAR	weight
Most cancer	0.7	0.3	0.7
Lung	0.3	0.7	0.3
Breast	0.0	1.0	0.0
Thyroid	1.0	0.0	1.0
Gallbladder	1.0	0.0	1.0
Brain/CNS	1.0	0.0	1.0

Dose and dose-rate effectiveness factor (DDREF) is the logical option to select 242 whether or not to consider 'DDREF' for computing LAR values. The value 'DDREF' is 243 to modify the effect of exposure to low-dose. The value of 'DDREF' is considered 244 differently as per exposure rate. However, if the site is leukemia, DDREF dose not 245 apply even if DDREF = TRUE. 246

#### Estimating LAR values using LAR, LAR\_batch and LAR\_group

To describe how to use functions installed in the **LARisk** package, we use the toy data 'nuclear', also installed in **LARisk**, assuming scenario of the data in which everyone is exposed to radiation at the same time in 2011. The data includes 20 people for 10 males and 10 females, and the radiation exposed age has ranges from 3 to 81 years with acute exposed rate and fixed dose distribution.

> nuclear > print(n	<pre>d &lt;- nuclear[: uclear1)</pre>	nuclear <mark>\$</mark> ID==" <mark>ID</mark>	001",]	
ID sex	birth expo	sure site	exposure_rate	dosedist
dc	sel dose2 dos	e3 distance		
ID01 fema	le 1973 :	2011 ovary	acute	fixedvalue
50.06	989 NA 1	NA 1		
ID01 fema	le 1973 :	2011 oesophagus	acute	fixedvalue
50.37	462 NA 1	NA 1		

LAR, LAR\_batch, and LAR\_group functions provide 3 main estimated values 264 such as lifetime risk, future risk and lifetime baseline risk. Among them, 'LAR' and 'F\_LAR' in Table 4 have mean values and confidence limits (lower and upper) for each cancer site, solid cancer and total (solid cancer+leukemia), respectively. See Table 4 for more details. 266

Table 4. Values in the LARisk package

Value	Description
LAR	Lifetime attributable risk (Cancer incidence probability per 100,000 persons after exposed year)
F_LAR	Future LAR (LAR after current year)
LBR	Lifetime baseline risk (Cumulative baseline probability per 100,000 persons of having cancer
	over the maximum lifetime without radiation exposure after exposed year)
BFR	Baseline future risk (Cumulative baseline probability per 100,000 persons of having cancer
	over the maximum lifetime without radiation exposure after current year
LFR	Lifetime fractional risk $(=LAR/LBR)$
$\mathrm{TFR}$	Total future risk (= $F_{AR} + BFR$ )

The LAR function prints the total LAR, future LAR, baseline future risk, and total future risk. If you want to obtain more detailed result, you can use the 'summary' 270 function. The 'summary' function provides the person's gender and year of birth, and risks by cancer type, confidence level, and current year. In the result, the 'LAR' tab includes site-specific LAR, LBR, and LFR, whereas the 'Future LAR' tab contains site-specific future LAR, BFR, and TFR. 274

```
> LAR(nuclear1, basedata = list(life2010, incid2010))
LAR:
                       Upper
Lower
            Mean
359.9479
           671.3751 1203.8111
Future
       LAR:
Lower
              Mean
                        Upper
         337.3697
                                 1032.216
F.LAR
                      597.7655
BFR
       15992.9219
                   15992 9219
                                15992 922
TFR
       16330.2917
                   16590.6874 17025.137
> summary(LAR(nuclear1, basedata = list(life2010, incid2010)))
Information:
sex birth
female
         1973
LAR:
Lower
                      Upper
                                     LBR
                                             LFR
            Mean
              74.5065
                                   2\,4\,1\,.\,1\,7\,1\,7
lung
                       156.5247
                                              3630.3464 0.0431
ovary
               4.4880
                        13.3756
                                    27.6491
                                               697.6095
                                                         0.0192
bladder
              13.0799
                        30.4405
                                    58.7444
                                               452.0590
                                                         0.0673
thyroid
              83.9986
                       368.7603
                                   877.5446
                                              7318.8901
                                                          0.0504
remainder
              33.5177
                        89.1794
                                   169.3327
                                              4237.3935
                                                          0.0210
oesophagus
               0.2000
                         4.0450
                                    10.4666
                                               116.7920
                                                          0.0346
               0.2670
                         9.0496
                                    21.7567
                                              2\,1\,5\,7.6\,2\,9\,4
                                                          0.0042
rectum
               0.0000
                         0.0000
                                     0.0000
                                                 0.0000
leukemia
                                                             NaN
                                                         0.0361
\operatorname{solid}
            359.9479
                       671.3751
                                  1203.8111
                                             18610.7199
total
            359.9479
                       671.3751
                                  1203.8111
                                             18610.7199
                                                          0.0361
Future LAR:
Lower
           Mean
                      Upper
                                     BFR
                                                 TFR
              73.4884
                       154.5469
                                   238.6027
                                              3574.2001
                                                           3728.7470
lung
                                    25.2806
                                               597.5191
ovary
               4.0861
                        12.0693
                                                            609.5885
bladder
              13.0173
                        30.3006
                                    58.5236
                                               452.9404
                                                            483.2410
thyroid
              68.7104
                       303.3691
                                   745.8708
                                              5117.1159
                                                           5420.4850
                        84.9052
remainder
              32.3341
                                   160.5547
                                              4066.5835
                                                           4151.4887
oesophagus
               0.1978
                         3.9420
                                    10.2253
                                               115.9270
                                                            119.8690
rectum
               0.2558
                         8.6324
                                    20.6083
                                              2068.6359
                                                           2077.2682
leukemia
               0.0000
                         0.0000
                                     0.0000
                                                  0.0000
                                                              0.0000
\operatorname{solid}
             337.3697
                       597.7655
                                  1032.2155
                                             15992.9219
                                                          16590.6874
            337.3697 597.7655
                                 1032.2155 15992.9219
total
                                                         16590.6874
```

378

277

278

279

280 281

282

283

284

285

286 287

288

289

290

291 292

293

294

295

296

297

298

299

300

301

302

303

304 305

306

307

308

309

310

311

312

313

314

315

316

Current Vear 2022	Confidence Level: 0.9	
	Current Year: 2022	

If you compute LAR values for many individuals, you can use the **LAR\_batch** function. Unlike **LAR**, **LAR\_batch** calculates each person' risk after reading multiple people's data at once. For example, suppose that we want to calculate the LAR values in the toy data 'nuclear' with person "ID". The sums of LAR values of all cancers for 3 observations are computed as follows. Here the argument 'max.id' means the number of individuals that should be printed.

<pre>&gt; ex_batch &lt;- LAR_batch(nuclear, pid=nuclear\$ID, basedata =</pre>
LAR: Lower Mean Upper 359.9479 671.3751 1203.8111
Future LAR:       Lower       Mean       Upper         F.LAR       337.3697       597.7655       1032.216         BFR       15992.9219       15992.9219       15992.922         TFR       16330.2917       16590.6874       17025.137
LAR result of ID02

Similarly, using the 'summary' function, you can get more detailed results for each cancer site as follows.

Information:						
temale 19	73					
LAR:						
Lower	Mean	Upper	LBR	LFR		
lung	74.5065	156.5247	241.1717	3630.3464	0.0431	
ovary	4.4880	13.3756	27.6491	697.6095	0.0192	
bladder	13.0799	30.4405	58.7444	452.0590	0.0673	
thyroid	83.9986	368.7603	877.5446	7318.8901	0.0504	
remainder	33.5177	89.1794	169.3327	4237.3935	0.0210	
oesophagus	0.2000	4.0450	10.4666	116.7920	0.0346	
rectum	0.2670	9.0496	21.7567	2157.6294	0.0042	
leukemia	0.0000	0.0000	0.0000	0.0000	NaN	
solid	359.9479	671.3751	1203.8111	18610.7199	0.0361	
total	359.9479	671.3751	1203.8111	18610.7199	0.0361	
Future LAR	:					
Lower	Mean	Upper	BFR	TFR		
lung	73.4884	154.5469	238.6027	3574.2001	3728.7470	
ovary	4.0861	12.0693	25.2806	597.5191	609.5885	
bladder	13.0173	30.3006	58.5236	452.9404	483.2410	
thyroid	68.7104	303.3691	745.8708	5117.1159	5420.4850	
remainder	32.3341	84.9052	160.5547	4066.5835	4151.4887	
oesophagus	0.1978	3.9420	10.2253	115.9270	119.8690	
rectum	0.2558	8.6324	20.6083	2068.6359	2077.2682	
leukemia	0.0000	0.0000	0.0000	0.0000	0.0000	
solid	337.3697	597.7655	1032.2155	15992.9219	16590.6874	
total	337.3697	597.7655	1032.2155	15992.9219	16590.6874	

The LAR\_group function averages estimated LAR values by group, which provides grouped LAR, grouped future LAR, and grouped baseline risk values for each group.

> ex\_group1 <- LAR\_group(nuclear, pid = nuclear\$ID, group = nuclear\$distance, basedata = list(life2010, incid2010)) > summary(ex\_group1) summaries of LAR result : Group 1 Group Information: birth 35 1962.600 sex count female male 45 1962.222 LAR: Lower Mean Upper LBR LFR 66.2373 stomach 50.985087.8936 2926.17140.0226 colon43.430156.127472.3353 2160.08320.0260liver 7.065710.493315.2987808.97720.0130lung 39.1538 53.479170.69983097.9930 0.01732.86364.28216.0646331.25760.0129breast 0.3206 0.955449.8292 ovary 1.97490.0192uterus 0.02160.14910.328868.46650.0022prostate -15.49176.274327.6037960.8121 0.006510.512216.159823.8353 430.75530.0375 bladder 0.74141.3918 2.299846.35920.0300 brain/cns thyroid 67.7618 185.2396350.2187 1648.0018 0.1124 34.546856.879388.6948 912.39920.0623remainder 0.3038 2.7663 105.26750.0127 oral 1.3365 5.3313 2.72558.1798 208.5186oesophagus 0.0256 rectum 0.3667 1.37772.5946618.5623 0.0022 gallbladder -6.2708-0.93364.2742420.9955-0.00227.406411.9408 493.6795 pancreas 3.43770.01503.2226 kidney 1.0530 6.5984203.1165 0.0159 leukemia 0.0713 0.2012 0.567719.9927 0.0101339.2210 475.4092659.3305 15491.2456 solid 0.0307 total 339.4012 475.6104 659.5318 15511.23840.0307 Future LAR: Lower Mean Upper BFR. TFR. stomach 48.229463.354284.7154 2490.03712553.3913colon 40.9639 53.454169.9636 1902.1381 1955.5921 6.04189.0587 13.2437571.8794580.9381liver lung 38.4091 52.564269.9525 2877.22432929.7885 2.3678 3.56445.0447157.2215160.7859breast 0.29190.862142.679943.5420ovary 1.8058 0.0203 0.1258 0.2655 uterus 41.5060 41.6318 -15.58876.222627.5255881.1613 887.3839 prostate 10.327616.0169 23.7049387.4721bladder 403.4890 36.5837brain / cns 0.62201.13731.855235.4464thyroid 60.0224 170.7748 330.0385 1233.1081 1403.8830 54.9135892.7615 33.7594remainder 84.8616 837.8480 1.25822.665189.1643 oral 0.266887.9061 oesophagus 4.4985 162.4755 2.43426.7130166.9740 0.33371.29612.4649524.0167525.3128rectum gallbladder -6.0139-0.87914.1981 361.3716 360.4925 pancreas 7.1431 3.245011.5463453.7292460.8723 187.0887 kidnev 0.97213.13876.5336 183.95000.08270.266713.7139leukemia 0.148513.8624318 3267 448 5040 621 6234 13231 1713 13679.6753solid  $318.4752\ 448.6524\ 621.7718\ 13244.8852\ 13693.5376$ total Confidence Level: 0.9 Current Year: 2022 summaries of LAR result : Group 2 Group Information: sex count birth12 1987.417 female male 5 1956.000

The average LAR values in the toy data 'nuclear' can be computed by 'distance' as follows.

395

396 398

399

400

401

402 403

404

405

406

407 408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431 432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455 456

457

458 459 460

461 462

463

464

465

Saving outputs	4
$LARisk$ includes a function write_LAR which writes outputs from LAR,	47
<b>LAR_batch</b> , and <b>LAR_group</b> into a CSV file.	47
> write LAR(x, filename)	4

The format of the saved file is illustrated in Table 5.

#### Table 5. Format to save outputs using a write\_LAR function

	Lower	Mean	Upper	F.Lower	F.Mean	F.Upper	LBR	BFR	LFR	$\mathrm{TFR}$
site-name	·	•	·	•	•	•	•	•	•	•
solid	•	•	•			•	•	•	•	•
total	•	•	•	•	•		•	•	•	•

# An example for chronic exposure rate with a toy data 'organ'

In this section, we consider a toy data 'organ' which consists of the 20 radiation exposed people over various periods with 14 males and 6 females having the job information 'occup'. The data is shown as follows.

> head(organ ID sex birt]	) h exposure	9	site expos	ure_rate c	losedist
da	ose1 dose2	dose3 d	occup	, .	C' 1 1
1 ID01 male 0.001954	1985 895 NA	2011 oe NA	sophagus 1	chronic	fixedvalue
2 ID01 male	1985	2011	kidney	chronic	fixedvalue
0.003855	487 NA	NA	1		

Suppose that we want to calculate LAR values with the current year=2021 using the Korean population in 2018. First, we compute LAR values with 'ID01' as follows.

```
>  organ1 <- organ[organ$ID='ID01',]
> ex_organ1 <- LAR(organ1, baseda=list(life2018, incid2018),
    current = 2021)
> ex_organ1
LAR:
Lower
         Mean Upper
1.1149 1.6981 2.5132
Future LAR:
Lower
            Mean
                      Upper
                                 2.4744
F.LAR
          1.1132
                     1.6759
BFR
       6694.6423 \ \ 6694.6423 \ \ 6694.6423
TFR.
      6695.7555 6696.3182 6697.1167
> summary(ex_organ1)
Information:
sex birth
male 1985
LAR:
Lower
         Mean Upper
                            LBR
                                  LFR
thyroid
            0.4673 0.9709 1.8205 1771.543 5e-04
oesophagus
            0.1025 \ 0.1824 \ 0.2729
                                    1048.947 \ 2e - 04
rectum
            0.0978 0.2385 0.4111
                                    2893.126
                                              1 \, \mathrm{e} - 04
kidney
            0.1416 \ 0.3064 \ 0.5160
                                    1338.149
                                              2e-04
leukemia
            0.0000 \ 0.0000 \ 0.0000
                                       0.000
                                                NaN
            1.1149
                    1.6981
                            2.5132
                                    7051.764
\operatorname{solid}
                                              2e - 04
            1.1149 1.6981 2.5132 7051.764 2e-04
total
Future LAR:
              Upper
                            BFR
                                      TFR
Lower
        Mean
thyroid
            0.4507 \ 0.9512 \ 1.7587 \ 1453.492 \ 1454.443
```

478

479

480

481

482

494

495 499

498

499

500

501

502

503

504 505

506

507

508

509

510 511

512

513

514

515 516

517

518

519

520

521

522

523

524

525 526

527

528

oesophagus	0.1025	0.1823	0.2728	1055.583	1055.766	530
rectum	0.0977	0.2379	0.4108	2877.117	2877.355	531
kidney	0.1406	0.3045	0.5153	1308.450	1308.755	532
leukemia	0.0000	0.0000	0.0000	0.000	0.000	533
solid	1.1132	1.6759	2.4744	6694.642	6696.318	534
total	1.1132	1.6759	2.4744	6694.642	6696.318	535
						536
Confidence	Level:	0.9				537
Current Ye	ar: 2021	1				538

The estimated total LAR values of the person 'ID01' is 1.6981 with the 90% confidence interval (1.1149, 2.5132) and the future risk is 1.6759 with the 90% confidence interval (1.1132, 2.4744). The person 'ID01' is a man born in 1985. 'ID01' was exposed to thyroid, oesophagus, 'rectum', and kidney except for leukemia. Thus, The LAR values of leukemia are all 0.

We also compute LAR values by group - male and female using **LAR\_group** as follows.

						1		
<pre>&gt; ex_organ2 &lt;- LAR_group(organ, pid=organ\$ID, group=organ\$sex, basedata=list(life2018, incid2018), current=2021)</pre>								
> summary(ex_organ2)								
summaries of LAR result : Group female								
Group Information: sex count birth								
female 166	1976.31	3						
LAR:								
Lower Mea	n Upp	er	LBR	LFR				
colon	0.6832	1.1392	1.7064	1080.1190	0.0011			
lung	2.3739	2.8990	3.5941	1353 2750	0.0021			
utorus	0 1447	0.2874	0 4696	338 1363	0.0008			
bloddor	0.0560	1 2026	1 7520	155 0491	0.0000			
	0.9000	1.5020	6 7600	1975 6971	0.0034			
remainder	2.9903	4.0000	0.7092	10/0.00/1	0.0024			
oral	0.1509	0.2311	0.3413	130.7238	0.0018			
oesophagus	0.0203	0.0768	0.1583	18.0691	0.0043			
rectum	0.2375	0.4315	0.6480	873.1753	0.0005			
gallbladder	-0.1736	-0.0274	0.1067	290.7825	-0.0001			
pancreas	0.0661	0.1089	0.1608	283.0072	0.0004			
leukemia	0.0792	0.1800	0.4092	81.1517	0.0022			
solid	9.3445	11.0056	13.3345	6398.9234	0.0017			
total	9.5265	11.1856	13.5145	6480.0751	0.0017			
Future LAR:								
Lower Mea	n Upp	er	BFR	TFR				
colon	0.6658	1.0964	1.6314	1051.6541	1052.7505			
lung	2.3673	2.8906	3.5837	1352.5231	1355.4137			
uterus	0 1423	0 2825	0 4686	296 3270	296 6095			
bladder	0.9503	1 2016	1 7359	154 4180	155 7096			
romaindor	2 8042	4 4153	6 5400	1702 3071	1706 8194			
oral	2.0342	4.4100	0.9409	110 1106	110 2277			
01a1	0.1444	0.2181	0.3177	119.1190	19.3377			
oesopnagus	0.0201	0.0762	0.1568	18.0923	18.1085			
rectum	0.2346	0.4186	0.6327	835.6204	836.0390			
gallbladder	-0.1735	-0.0274	0.1066	292.4045	292.3771			
pancreas	0.0653	0.1079	0.1591	281.1836	281.2915			
leukemia	0.0944	0.1773	0.3603	77.5662	77.7435			
solid	9.1382	10.7697	12.9982	6193.7399	6204.5095			
total	9.3172	10.9470	13.1770	6271.3060	6282.2530			
Confidence I	Level: 0	. 9						
Current Year	: 2021							
summaries of	LAR res	sult : G	roup male	е				
Confidence I	evel: 0	. 9						
Current Year	: 2021							

The above results illustrate that the estimated average LAR values (90% confidence intervals) for female and male are 11.1856(9.5265, 13.5145) and

27.1674(23.8700, 28.7939), respectively. **LAR\_group** can consider two group variables such as gender and occupation in this toy 'organ' data as follows.

```
> ex_organ3 <- LAR_group(organ, pid=organ$ID, group=list(organ$
    sex, organ$occup), basedata=list(life2018, incid2018),
    current = 2021)
> print(ex_organ3, max.id=2)
LAR result of female.1
LAR:
Lower
        Mean Upper
4.7547 6.2051 8.0758
Future LAR:
                     Upper
Lower
           Mean
F.LAR
         4.7348
                    6.1773
                               8.0388
BFR.
      3746.8142 \ 3746.8142 \ 3746.8142
TFR
      3751.5490 3752.9915 3754.8530
LAR result of male.1
LAR:
         Mean
                 Upper
Lower
37.9314 41.3941 45.0670
Future LAR:
Lower
            Mean
                       Upper
F.LAR
         32.3847
                     35.4936
                                 38.7843
BFR
      12300.1490 \ 12300.1490
                             12300.1490
TFR
      12332.5337 12335.6426 12338.9333
The results for 5 groups are omitted.
```

## Concluding remarks

We proposed the **LARisk** package built in R to calculate projected and/or lifetime radiation related cancer risks after exposure. We described and considered the various uncertainties in the lifetime risk calculations to construct this package. Three main flexible and useful functions were developed, and many arguments/options are available to promptly update new knowledge from radiation epidemiology and related fields. Of particular interest is the ability to input population information, replacing cancer incidence rates and survival functions for the population of interest and observed year to be used for lifetime risk calculation. This greatly simplifies to employ new baseline incidence rate and population survival rate data for a given year. Detailed description of the arguments/options and related data formats, etc. are provided in the LARisk vignette (https://cran.r-project.org/web/packages/LARisk/vignettes/LARisk-vignette.html).

**LARisk** is an effective and simple method to calculate excess lifetime risk from radiation exposure, and can be applied to any population of interest.

## References

- Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiation research. 2007;168(1):1–64.
- 2. Carpeggiani C, Paterni M, Caramella D, Vano E, Semelka RC, Picano E. A novel tool for user-friendly estimation of natural, diagnostic and professional radiation risk: Radio-Risk software. European journal of radiology. 2012;81(11):3563–3567.

604

605 889

608

609

610 611

612

613 614

615

616

617 618

619

620

621

622

623 624 625

626 627

628

629

630 631

632

633

634

635

636 637

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

- Journy NMY, Lee C, Harbron RW, McHugh K, Pearce MS, Berrington de González A. Projected cancer risks potentially related to past, current, and future practices in paediatric CT in the United Kingdom, 1990–2020. British journal of cancer. 2017;116(1):109.
- 4. Berrington de Gonzalez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Archives of Internal Medicine. 2009;169(22):2071–2077.
- Evans JS, Abrahamson S, Bender MA, Boecker BB, Gilbert ES, Scott BR. Health effects models for nuclear power plant accident consequence analysis. Rev. 2 PART II, NUREG/CR-4214. U.S. Nuclear Regulatory Commission; 1993.
- NRC. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2 (National Research Council and others). vol. 7. National Academies Press; 2006.
- Seo S, Lee DN, Jin YW, Lee WJ, Park S. Usefulness of cancer-free survival in estimating the incidence from radiation exposure. Journal of Radiological Protection. 2018;38(3):N17–N24.
- Thomas D, Darby S, Fagnani F, Hubert P, Vaeth M, Weiss K. Definition and estimation of lifetime detriment from radiation exposures: principles and methods. Health Physics. 1992;63(3):259–272.
- Vaeth M, Pierce DA. Calculating excess lifetime risk in relative risk models. Environmental Health Perspectives. 1990;87:83–94.
- Kellerer AM, Nekolla EA, Walsh L. On the conversion of solid cancer excess relative risk into lifetime attributable risk. Radiation and environmental biophysics. 2001;40(4):249–257.
- WHO. Health risk assessment from the nuclear accident after the 2011 Great East Japan earthquake and tsunami, based on a preliminary dose estimation. vol. 7. World Health Organization; 2013.
- Faletra FF, DÁngeli I, Klersy C, Averaimo M, Klimusina J, Pasotti E, et al. Estimates of after a single radiation exposure from 64-slice computed tomographic coronary angiography. Heart. 2010;96(12):927–932.
- 13. Koral K, Blackburn T, Bailey AA, Koral KM, Anderson J. Strengthening the argument for rapid brain MR imaging: estimation of reduction in lifetime attributable risk of developing fatal cancer in children with shunted hydrocephalus by instituting a rapid brain MR imaging protocol in lieu of Head C. American Journal of Neuroradiology. 2012;33(10):1851–1854.
- 14. Aw-Zoretic J, Seth D, Katzman G, Sammet S. Estimation of effective dose and lifetime attributable risk from multiple head CT scans in ventriculoperitoneal shunted children. European Journal of Radiology. 2014;83(10):1920–1924.
- Ivanov VK, Kashcheev VV, Chekin SY, Menyaylo AN, Pryakhin EA, Tsyb AF, et al. Estimating the lifetime risk of cancer associated with multiple CT scans. Journal of Radiological Protection. 2014;34(4):825–841.
- 16. Journy N, Ancelet S, Rehel JL, Mezzarobba M, Aubert B, Laurier D, et al. Predicted cancer risks induced by computed tomography examinations during childhood, by a quantitative risk assessment approach. Radiation and Environmental Biophysics. 2014;53(1):39–54.

- Salibi PN, Agarwal V, Panczykowski DM, Puccio AM, Sheetz MA, Okonkwo DO. from CT among patients surviving severe traumatic brain injury. American Journal of Roentgenology. 2014;202(2):397–400.
- 18. Hoang JK, Reiman RE, Nguyen GB, Januzis N, Chin BB, Lowry C, et al. Lifetime Attributable Risk of Cancer From Radiation Exposure During Parathyroid Imaging: Comparison of 4D CT and Parathyroid Scintigraphy. American Journal of Roentgenology. 2015;204(5):W579–W585.
- Andersson M, Eckerman K, Mattsson S. Lifetime attributable risk as an alternative to effective dose to describe the risk of cancer for patients in diagnostic and therapeutic nuclear medicine. Physics in Medicine and Biology. 2017;62(24):9177–9188.
- Journy NM, Lee C, Harbon RW, McHugh MS K Pearce, Berrington de Gonzalez A. Projected cancer risks potentially related to past, current, and future practices in paediatric CT in the United Kingdom, 1990-2020. British Journal of Cancers. 2017;116(1):109–116.
- 21. Tamura M, Sakurai H, Mizumoto M, Kamizawa S, Murayama S, Yamashita H, et al. Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients. Journal of Radiation Research. 2017;58(3):363–371.
- 22. Branchini M, Del Vecchio A, Gigliotti CR, Loria A, Zerbi A, Calandrino R. Organ doses and lifetime attributable risk evaluations for scoliosis examinations of adolescent patients with the EOS imaging system. European Journal of Trauma and Emergency Surgery. 2018;123(4):305–313.
- Berrington De Gonzalez A, Apostoaei AI, Veiga LHS, Rajaraman P, Thomas BA, Hoffman FO, et al. RadRAT: a radiation risk assessment tool for lifetime cancer risk projection. Journal of Radiological Protection. 2012;32(3):205.
- 24. Lee WJ, Choi Y, Ko S, Cha ES, Kim J, Kim YM, et al. Projected lifetime cancer risks from occupational radiation exposure among diagnostic medical radiation workers in South Korea. BMC cancer. 2018;18(1):1206.
- 25. Fresco R, Spera G, Meyer C, Cabral P, Mackey JR. Imaging radiation doses and associated risks and benefits in subjects participating in breast cancer clinical trials. The oncologist. 2015;20(7):702–712.
- 26. Furukawa K, Cologne JB, Shimizu Y, Cullings HM. Predicting future excess events in risk assessment. Risk Analysis. 2009;29(6):885–899.
- Furukawa K, Misumi M, Cologne JB, Cullings HM. A Bayesian semiparametric model for radiation dose-response estimation. Risk Analysis. 2016;36(6):1211–1223.
- Richardson DB, Cardis E, Daniels RB, Gilies M, Haylock R, Leurand K, et al. Site-specific solid cancer mortality after exposure to ionizing radiation: A cohort study of workers (INWORKS). Epidemiology. 2018;29(1):31–40.
- 29. Turner H, Firth D. Generalized nonlinear models in R: An overview of the gnm package. ESRC National Centre for Research Methods; 2007.

- 30. Rühm W, Woloschak GE, Shore RE, Azizova TV, Grosche B, Niwa O, et al. Dose and dose-rate effects of ionizing radiation: a discussion in the light of radiological protection. Radiation and Environmental Biophysics. 2015;54(4):379–401.
- 31. Little MP, Pawel D, Misumi M, Hamada N, Cullings HM, Wakeford R, et al. Lifetime Mortality Risk from Cancer and Circulatory Disease Predicted from the Japanese Atomic Bomb Survivor Life Span Study Data Taking Account of Dose Measurement Error. Radiation Research. 2020;194(3):259–276.
- 32. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103; 2007.
- 33. Land C, Gilbert E, Smith JM, Hoffman FO, Apostoaei AI, Thomas B, et al. Report of the NCI-CDC working group to revise the 1985 NIH radioepidemiological tables. US Department of Health and Human Services, National Institutes of Health ; 2003.